Effect of quercetin in treatment of stroke
Phase 3
- Conditions
- cerebral infarction( ischemic stroke).Cerebral infarction
- Registration Number
- IRCT201202269142N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
patients in the chronic phase of ischemic stroke
( 6 month- 2 years), 50- 75 years old, Body mass index between 25- 35.
Exclusion criteria:
Body mass index more than 35, Body mass index under 25, liver disease, kidney disease, hypo or hyper thyroid, Hemorrhagic stroke, Hormone therapy (HRT), intake of warfarin.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Asymmetric Dimethylarginine. Timepoint: Start of survey and end of the second month. Method of measurement: Micromol/L with Human ADMA ELISA Kit.
- Secondary Outcome Measures
Name Time Method Total cholesterol. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Triglyceride. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Low density lipoprotein. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;High density lipoprotein. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Fast blood glucose. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Blood pressure. Timepoint: Start of survey and end of the second month. Method of measurement: mmgh.